Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer’s Disease

Linna, Miika; Vuoti, Sauli; Silander, Katariina; Hörhammer, Iiris; Halminen, Olli; Mikkola, Teija; Koivuranta-Vaara, P; Virta, Lauri J.; Koivusalo, Mirkka; Ylisaukko-oja, Tero

doi:10.3233/jad-190288

Cited by 9 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main reason was the participants considered that AD is currently incurable and the diagnosis would be of little signi cance, indicating that some people are still insu ciently aware of AD treatment. Although AD cannot be completely cured at present, a large number of studies have shown that early diagnosis and reasonable treatment can effectively delay disease progression and reduce the economic burden on families and society [18][19][20]. In 2019, the China Food and Drug Administration (CFDA) approved Sodium Oligomannate for the treatment of mild-moderate AD, which can effectively improve the cognitive function of AD patients and delay the progression of the disease [21][22][23].…”

Section: Discussionmentioning

confidence: 99%

Knowledge of the public about the role of lumbar puncture in the diagnosis of Alzheimer's disease in China

Guo

Gao

Jin

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Lumbar puncture for cerebrospinal fluid (CSF) detection has not been widely used in clinical practice in China. The aim of this study was to investigate the knowledge of the public about the role of lumbar puncture in the diagnosis of Alzheimer's disease (AD).Methods: A questionnaire survey was conducted using the "Sojump" application. The participants followed the instruction to answer the questionnaire on mobile phone. The survey included the demographic data of the participants, the knowledge about the role of lumbar puncture in the diagnosis of AD, the reasons to decide to undergo lumbar puncture examination. Univariate analysis and multivariate logistic regression analysis were used to investigate the factors associated with the decision. Results: A total of 1050 valid questionnaires were collected, including 403 (38.4%) non-medical staff and 647 (61.6%) medical staff. A total of 862 participants (82.1%) were willing to undergo lumbar puncture, of whom 508 (58.9%) considered that it was helpful to confirm the diagnosis. Multivariate analysis showed that the factors associated with willingness in non-medical staff included: age (OR=0.963, P=0.003, 95% CI: 0.939-0.987), education level (OR=2.073, P=0.037, 95% CI: 1.044-4.114), monthly income (OR=1.340, P=0.031, 95% CI: 1.028-1.748), and occupation type (OR=1.569, P=0.038, 95% CI: 1.026-2.400). The factors associated with willingness in medical staff included: residence (OR=9.182, P=0.036, 95% CI: 1.151-73.238), monthly income (OR=4.008, P=0.002, 95% CI: 1.689-9.511), and hospital Level (OR=38.311, P<0.001, 95% CI: 14.323-102.478).Conclusions: In the general population, more than 80% of people were willing to undergo lumbar puncture for AD diagnosis. However, the desire for the lumbar puncture depends on age, education level, economic status and occupation type.

show abstract

Section: Discussionmentioning

confidence: 99%

Knowledge of the public about the role of lumbar puncture in the diagnosis of Alzheimer's disease in China

Guo

Gao

Jin

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…It has also been shown that ChEIs and memantine are not effective in restoring cognitive function and relieving neuropsychiatric symptoms in patients with poor overall outcomes 36 . However, ChEIs and memantine reduce the risk of death in patients with AD, and donepezil has a greater ability to reduce the risk of death than memantine 34 . High doses of Rivastigmine patches have been shown to be very effective in functional recovery and initial diagnosis.…”

Section: Memantine Therapy For Admentioning

confidence: 99%

“…The loss of cholinergic nerves in the basal forebrain of AD patients results in the denervation of presynaptic cholinergic neurons. ChEIs compensate for the decrease in cholinergic energy in patients by inhibiting acetylcholine catabolism and enhancing interneural message transmission 34 . Memantine inhibits the excessive activation of NMDA receptors, thereby antagonizing glutamine‐mediated excitotoxicity to neuronal damage.…”

Section: Memantine Therapy For Admentioning

confidence: 99%

“…ChEIs compensate for the decrease in cholinergic energy in patients by inhibiting acetylcholine catabolism and enhancing interneural message transmission. 34 Memantine inhibits the excessive activation of NMDA receptors, thereby antagonizing glutamine‐mediated excitotoxicity to neuronal damage. Memantine also enhances cholinergic signaling and, like ChEIs, can reduce acetylcholine deficiency in AD patients.…”

Section: Memantine Therapy For Admentioning

confidence: 99%

See 1 more Smart Citation

Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications

Tang

Wang

Ren

2023

Ibrain

View full text Add to dashboard Cite

Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world. AD is nonreversible, and memantine can only relieve the symptoms of AD but not cure it. Over the past half‐century, memantine's research and clinical application have been extensively developed. In this review, the basic composition of memantine, the mechanism and limitations of memantine in the treatment of AD, memantine combination therapy, comparison of memantine with other drugs for AD, and clinical studies of memantine in other diseases are reviewed to provide a valuable reference for further research and application of memantine for the treatment of AD.

show abstract

“…This modelling approach will give us an estimation of the effect of various individual characteristics on care transition. In particular, we can estimate the effect of separate pharmacological therapies on care transition by including one dummy variable 𝛽𝛽 𝑚𝑚𝑑𝑑𝑑𝑑 𝑡𝑡−1 per therapy to the equation (Linna, Vuoti, et al, 2019). Continuing, we can also model the effect of pharmaceutical therapies on risk of dying by considering death as one (absorbing) long-term state (Halminen, Vesikansa, et al, 2021).…”

Section: Risk Of a Care Transitionmentioning

confidence: 99%

Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer’s Disease Patients: A Finnish Nationwide Cohort Study

Halminen

Vesikansa²,

Mehtälä³

et al. 2021

JAD

Self Cite

View full text Add to dashboard Cite

Background: Dementia is one of the strongest predictors of admission to a 24-hour care facility among older people, and 24-hour care is the major cost of Alzheimer’s disease (AD). Objective: The aim of this study was to evaluate the association of early start of anti-dementia medication and other predisposing factors with 2-year risk of transition to 24-hour care in the nationwide cohort of Finnish AD patients. Methods: This was a retrospective, non-interventional study based on individual-level data from Finnish national health and social care registers. The incident cohort included 7,454 AD patients (ICD-10, G30) comprised of two subgroups: those living unassisted at home (n = 5,002), and those receiving professional home care (n = 2,452). The primary outcome was admission to a 24-hour care facility. Exploratory variables were early versus late anti-dementia medication start, sociodemographic variables, care intensity level, and comorbidities. Results: Early anti-dementia medication reduced the risk of admission to 24-hour care both in patients living unassisted at home, with a hazard ratio (HR) of 0.58 (p < 0.001), and those receiving professional home care (HR, 0.84; p = 0.039). Being unmarried (HR, 1.69; p < 0.001), having an informal caregiver (HR, 1.69; p = 0.003), or having a diagnosis of additional neurological disorder (HR, 1.68; p = 0.006) or hip fracture (HR, 1.61; p = 0.004) were associated with higher risk of admission to 24-hour care in patients living unassisted at home. Conclusion: To support living at home, early start of anti-dementia medication should be a high priority in newly diagnosed AD patients.

show abstract

Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer’s Disease

Cited by 9 publications

References 40 publications

Knowledge of the public about the role of lumbar puncture in the diagnosis of Alzheimer's disease in China

Knowledge of the public about the role of lumbar puncture in the diagnosis of Alzheimer's disease in China

Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications

Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer’s Disease Patients: A Finnish Nationwide Cohort Study

Contact Info

Product

Resources

About